Skrha J, Hodinár A, Kvasnicka J, Stibor V, Sperl M, Stolba P, Hilgertová J
Department of Internal Medicine 3, Faculty of Medicine 1, Charles University, Prague, Czech Republic.
Clin Chim Acta. 1994 Sep;229(1-2):5-14. doi: 10.1016/0009-8981(94)90224-0.
Biochemical markers of early changes that are characteristic for diabetic microangiopathy are not completely understood. We investigated activities of serum N-acetyl-beta-glucosaminidase (NAG), tissue plasminogen activator and erythrocyte superoxide dismutase in well defined groups of type 1 diabetic patients. Patients were selected on the basis of 4 year follow-up observation. Forty-two type 1 diabetic patients were subdivided into those without retinopathy (n = 13) throughout the study, those with newly developed or worsened retinopathy (n = 12) during 4 years and those with retinopathy already established at the beginning of the study and without evidence of its progression (n = 17). All diabetic patients had albustix-negative urine. A significant increase of the mean serum NAG activity during 4 years was found only in patients without retinopathy (P < 0.01) whereas no changes of the altered enzyme activities were present in patients with developing and established retinopathy. The mean activity of tissue plasminogen activator was elevated in all groups of diabetic patients compared with healthy subjects (P < 0.001). A significant positive correlation was found between plasminogen activator and serum NAG (r = 0.51, P < 0.01). Erythrocyte superoxide dismutase was higher in diabetic patients than in healthy persons (P < 0.01) but no differences were observed between the patients with or without retinopathy. Superoxide dismutase positively correlated with NAG (r = 0.57, P < 0.01). We conclude that early functional changes precede a morphological development of diabetic retinopathy as was evident from the altered enzyme activities.
目前对于糖尿病微血管病变早期特征性变化的生化标志物尚未完全了解。我们对明确分组的1型糖尿病患者血清N - 乙酰 - β - 氨基葡萄糖苷酶(NAG)、组织型纤溶酶原激活剂和红细胞超氧化物歧化酶的活性进行了研究。患者是基于4年的随访观察选取的。42例1型糖尿病患者被分为在整个研究过程中无视网膜病变的患者(n = 13)、在4年内出现新的或加重的视网膜病变的患者(n = 12)以及在研究开始时已有视网膜病变且无进展证据的患者(n = 17)。所有糖尿病患者尿糖试纸检测均为阴性。仅在无视网膜病变的患者中发现4年内血清NAG平均活性显著增加(P < 0.01),而在发生和已确诊视网膜病变的患者中,酶活性改变无变化。与健康受试者相比,所有糖尿病患者组的组织型纤溶酶原激活剂平均活性均升高(P < 0.001)。纤溶酶原激活剂与血清NAG之间存在显著正相关(r = 0.51,P < 0.01)。糖尿病患者的红细胞超氧化物歧化酶高于健康人(P < 0.01),但有或无视网膜病变的患者之间未观察到差异。超氧化物歧化酶与NAG呈正相关(r = 0.57,P < 0.01)。我们得出结论,从酶活性改变可以明显看出,糖尿病视网膜病变的形态学发展之前存在早期功能变化。